Ainuovirine vs Azvudine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Ainuovirine

Marketed by Jiangsu Aidea Pharmaceutical Group under a licence from Kainos Medicine

Phase 1 in HIVsmall molecule
Weak signal

NCT01348516 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Safety/ Tolerability Evaluation". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: June 2028 · NCT07631897 (registry estimate)

Reported efficacy

Safety/ Tolerability Evaluation (participants will be followed for the duration of hospital stay, 8-10 days for SAD and 14-16 days for MAD): In 80 healthy male volunteers given single or multiple doses (once daily for 7 days) of 75, 150, 300 or 600 mg or placebo, the drug was generally well tolerated with no serious adverse events and showed dose- and time-dependent nonlinear pharmacokinetics across the 75 to 600 mg range.

Result source: NCT01348516

Azvudine · FNC

Marketed by Henan Genuine Biotech

Phase 3 in HIVsmall molecule
Partial signal

NCT04303598 · Phase 3 · status unknown

This is a randomized, double-blind, active-controlled trial testing whether azvudine achieves viral suppression as well as an established comparator, using a recognized clinical measure of HIV control, but results are not yet posted so the outcome is unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

Reported efficacy

Evaluation of azivudine tablet (FNC) combined with reverse transcriptase inhibitor therapy without anti-hiv treatment. (At 48 weeks); Preliminary evaluation of the efficacy of azivudine tablets (FNC) combined with reverse transcriptase inhibitors in the treatment of patients who have not received anti-hiv treatment. (At 48 weeks): 符合方案集(PPS)阿兹夫定 2 mg 组、阿兹夫定 3 mg 组、阿兹夫定 4 mg 组和 3TC 组结果分别为 97.2%、100%、100% 和 97.5%。经卡方分析各组之间无显著统计学差异(P>0.05) (unclear)

Result source: NCT04109183

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAinuovirineAzvudine
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Not reported
CD4 count, change (week 48)—Not reported—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

Ainuovirine
—Not reported
Azvudine
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Ainuovirine
—Not reported
Azvudine
—Not reported

CD4 count, change (week 48)

Ainuovirine
—Not reported
Azvudine
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ainuovirine: no structured comparison results are available for HIV.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Azvudine
符合方案集(PPS)阿兹夫定 2 mg 组、阿兹夫定 3 mg 组、阿兹夫定 4 mg 组和 3TC 组结果分别为 97.2%、100%、100% 和 97.5%。经卡方分析各组之间无显著统计学差异(P>0.05) NCT04109183 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ainuovirine's landscape · Azvudine's landscape